Loading candles…
FDC Ltd, founded in 1936, operates in the pharmaceutical industry with a focus on manufacturing and marketing therapeutic formulations and Active Pharmaceutical Ingredients (APIs). The company is recognized as a pioneer in specialized formulations and a leading manufacturer and marketer of Oral Rehydration Salts (ORS), with its flagship brand Electral noted for its prominence in the ORS category. Its business segments include specialized formulations, ORS, and APIs. FDC's product portfolio features pharmaceutical formulations, oral rehydration salts, and active pharmaceutical ingredients. The company serves markets in India and exports to over 50 countries. Its leading brands include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zathrin, Zipod, Cotaryl, and Mycoderm.
| Audited Results - Q4 & FY26 |
| To consider and approve the Audited Standalone & Consolidated Financial Results of the Company for Quarter and Year ended March 31, 2026 |
| 27 May 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 and other business matters | 5 Feb 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025, dividend and other business matters | 5 Feb 2026 |
| Unaudited Results - FY25 | To consider and approve the unaudited financial results for the period ended September 30, 2025 and other business matters | 5 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 | 7 Aug 2025 |
| Audited Results - Q4 & FY25 | To consider and approve Audited Standalone & Consolidated Financial Results of the Company for Quarter and Year ended March 31, 2025. | 28 May 2025 |
Besseggen InfoTech LLP is a SEBI-registered stock broker (Reg. No. INZ000213450), member of NSE (90155 (Cash & F&O)) and BSE (6722 (Cash & F&O)). Investment in securities market are subject to market risks; read all related documents carefully before investing.